Reflecting its Growth, BIND Biosciences Changes Name to BIND Therapeutics
Prompted by Progress in Developing a Pipeline of Accurins: Highly Selective Targeted and Programmable Therapeutics
BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins™, today announced that, effective immediately, it will begin operating as BIND Therapeutics to reflect the Company’s progress in applying its Medicinal Nanoengineering® platform to develop a pipeline of highly selective targeted and programmable therapeutics called Accurins. Simultaneous with the name change, the company has launched a new corporate website and URL ‘www.BINDTHERAPEUTICS.COM’.
“The new name, BIND Therapeutics, conveys the company’s leadership and advancement in developing novel Accurins with unique therapeutic properties by selectively accumulating in diseased tissues and cells, resulting in high drug concentrations at the site of action with low off-target exposure, leading to markedly better efficacy and safety,” said Scott Minick, BIND’s President and CEO. “Our lead product candidate, BIND-014, has completed a Phase 1 clinical study in cancer patients and we are initiating Phase 2 clinical trials in multiple solid tumor types. In addition, we are also developing Accurins in collaboration with pharmaceutical and biotechnology partners including Amgen to enable their promising pipeline candidates to achieve their full potential.”
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its Medicinal Nanoengineering® platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND’s lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer.
BIND has announced collaborations with Amgen Inc., Pfizer Inc. and AstraZeneca AB to develop Accurins based on therapeutic payloads from their product pipelines. BIND’s platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women’s Hospital / Harvard Medical School of BIND’s scientific founders and directors Dr. Robert Langer and Dr. Omid Farokhzad.
For more information, please visit the company’s web site at www.bindtherapeutics.com